Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

"Liquid Biopsy" of Circulating Tumor DNA Characterizes Treatment Response in Pediatric Patients Diffuse Midline Glioma.

Traylor JI, Kuo JS.

Neurosurgery. 2019 Feb 22. pii: nyz029. doi: 10.1093/neuros/nyz029. [Epub ahead of print] No abstract available.

PMID:
30793197
2.

Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.

Huang TY, Piunti A, Lulla RR, Qi J, Horbinski CM, Tomita T, James CD, Shilatifard A, Saratsis AM.

Acta Neuropathol Commun. 2017 Apr 17;5(1):28. doi: 10.1186/s40478-017-0436-6.

3.

Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy.

Panditharatna E, Kilburn LB, Aboian MS, Kambhampati M, Gordish-Dressman H, Magge SN, Gupta N, Myseros JS, Hwang EI, Kline C, Crawford JR, Warren KE, Cha S, Liang WS, Berens ME, Packer RJ, Resnick AC, Prados M, Mueller S, Nazarian J.

Clin Cancer Res. 2018 Dec 1;24(23):5850-5859. doi: 10.1158/1078-0432.CCR-18-1345. Epub 2018 Oct 15.

4.

Liquid biopsies in patients with diffuse glioma.

Best MG, Sol N, Zijl S, Reijneveld JC, Wesseling P, Wurdinger T.

Acta Neuropathol. 2015 Jun;129(6):849-65. doi: 10.1007/s00401-015-1399-y. Epub 2015 Feb 27.

5.

Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.

Karremann M, Gielen GH, Hoffmann M, Wiese M, Colditz N, Warmuth-Metz M, Bison B, Claviez A, van Vuurden DG, von Bueren AO, Gessi M, Kühnle I, Hans VH, Benesch M, Sturm D, Kortmann RD, Waha A, Pietsch T, Kramm CM.

Neuro Oncol. 2018 Jan 10;20(1):123-131. doi: 10.1093/neuonc/nox149.

6.

Interpretation of magnetic resonance images in diffuse intrinsic pontine glioma: a survey of pediatric neurosurgeons.

Hankinson TC, Campagna EJ, Foreman NK, Handler MH.

J Neurosurg Pediatr. 2011 Jul;8(1):97-102. doi: 10.3171/2011.4.PEDS1180.

PMID:
21721895
7.

Molecular alterations in pediatric brainstem gliomas.

Porkholm M, Raunio A, Vainionpää R, Salonen T, Hernesniemi J, Valanne L, Satopää J, Karppinen A, Oinas M, Tynninen O, Pentikäinen V, Kivivuori SM.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26751. Epub 2017 Aug 9.

PMID:
28792659
8.

Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics.

Hoffman LM, DeWire M, Ryall S, Buczkowicz P, Leach J, Miles L, Ramani A, Brudno M, Kumar SS, Drissi R, Dexheimer P, Salloum R, Chow L, Hummel T, Stevenson C, Lu QR, Jones B, Witte D, Aronow B, Hawkins CE, Fouladi M.

Acta Neuropathol Commun. 2016 Jan 4;4:1. doi: 10.1186/s40478-015-0269-0. Erratum in: Acta Neuropathol Commun. 2016;4:13.

9.

Extending the Neuroanatomic Territory of Diffuse Midline Glioma, K27M Mutant: Pineal Region Origin.

Gilbert AR, Zaky W, Gokden M, Fuller CE, Ocal E, Leeds NE, Fuller GN.

Pediatr Neurosurg. 2018;53(1):59-63. doi: 10.1159/000481513. Epub 2017 Nov 4.

PMID:
29131126
10.

Diffuse midline gliomas with histone H3-K27M mutation: A rare case with PNET-like appearance and neuropil-like islands.

Gao Y, Feng YY, Yu JH, Li QC, Qiu XS, Wang EH.

Neuropathology. 2018 Apr;38(2):165-170. doi: 10.1111/neup.12413. Epub 2017 Sep 6.

PMID:
28880421
11.

Liquid Biopsy in Primary Brain Tumors: Looking for Stardust!

Fontanilles M, Duran-Peña A, Idbaih A.

Curr Neurol Neurosci Rep. 2018 Mar 9;18(3):13. doi: 10.1007/s11910-018-0820-z. Review.

PMID:
29520561
12.

Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes?

Zhang W, Xia W, Lv Z, Ni C, Xin Y, Yang L.

Cell Physiol Biochem. 2017;41(2):755-768. doi: 10.1159/000458736. Epub 2017 Feb 13. Review.

13.

Malignant primary diffuse leptomeningeal gliomatosis with histone H3.3 K27M mutation.

Champeaux C, Drier A, Devaux B, Tauziède-Espariat A.

Neurochirurgie. 2018 Jun;64(3):198-202. doi: 10.1016/j.neuchi.2017.12.007. Epub 2018 May 9.

PMID:
29752148
14.

Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant.

Banan R, Christians A, Bartels S, Lehmann U, Hartmann C.

Acta Neuropathol Commun. 2017 Dec 15;5(1):98. doi: 10.1186/s40478-017-0500-2. No abstract available.

15.

Applications of DNA-Based Liquid Biopsy for Central Nervous System Neoplasms.

Wang J, Bettegowda C.

J Mol Diagn. 2017 Jan;19(1):24-34. doi: 10.1016/j.jmoldx.2016.08.007. Epub 2016 Nov 15. Review.

PMID:
27863260
16.

Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA.

Li J, Han X, Yu X, Xu Z, Yang G, Liu B, Xiu P.

J Exp Clin Cancer Res. 2018 Sep 3;37(1):213. doi: 10.1186/s13046-018-0893-1. Review.

17.

The efficacy of a biopsy of intrinsic brainstem lesions for decision making of the treatments.

Ogiwara H, Morota N.

Childs Nerv Syst. 2013 May;29(5):833-7. doi: 10.1007/s00381-013-2042-7. Epub 2013 Feb 3.

PMID:
23377758
18.

Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma.

Wu FT, Lu L, Xu W, Li JY.

Ann Hematol. 2019 Feb;98(2):255-269. doi: 10.1007/s00277-018-3529-9. Epub 2018 Oct 27. Review.

PMID:
30368587
19.

Patient monitoring through liquid biopsies using circulating tumor DNA.

Ulz P, Heitzer E, Geigl JB, Speicher MR.

Int J Cancer. 2017 Sep 1;141(5):887-896. doi: 10.1002/ijc.30759. Epub 2017 May 25. Review.

20.

[Evaluation of radiation therapy in pediatric brain stem glioma by computed tomography: CT findings and tumor response to radiotherapy].

Mori S, Tanaka R, Takeda N, Yoshida S.

No Shinkei Geka. 1991 Feb;19(2):129-35. Japanese.

PMID:
2023668

Supplemental Content

Support Center